Clinical Trial Update: Study of Pembrolizumab as First Line Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating pembrolizumab as first-line therapy in unresectable squamous cell carcinoma of the skin.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Skin

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Carcinoma, Squamous Cell | Phase 2 | Status: COMPLETED